CAR-T therapy is listed as a current ACT modality examined for ovarian cancer.
First-pass extracted concept
chimeric antigen receptor T cell therapy
Candidate: concept label9 source documents23 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
CAR-T, CAR T cell therapy, CAR T-cell therapy, CAR-T cell therapy, CAR-T therapy, chimeric antigen receptor-T cell therapies
Extracted Explainers
What the tool is doing
CAR T cell therapy engineers patient-derived T cells ex vivo so they can recognize and eliminate tumor antigens.
The review identifies CAR-T therapy as a major adoptive cell therapy modality discussed at the congress. It is presented as part of the current cancer immunotherapy landscape.
CAR-T therapy is presented as a personalized and potent immunotherapeutic approach. The abstract states that it has revolutionized treatment in hematologic malignancies.
CAR-T therapy engineers autologous T cells with synthetic receptors so they can recognize tumor-associated antigens independently of major histocompatibility complex presentation.
CAR-T therapy is described as an investigational strategy targeting NF1-associated tumors.
CAR-T cell therapy is presented as an immunotherapy approach for pediatric B-ALL, particularly in relapsed or refractory disease. The abstract frames it as a transformative treatment class.
Resources required
It requires patient-derived T cells and an ex vivo engineering workflow.
The abstract states that autologous T cells must be engineered and that production can use viral vectors, transposons, CRISPR/Cas9, or RNA-based electroporation.
The approach requires a chimeric antigen receptor T cell therapy platform.
What problem it solves
It offers a way to direct immune cells against tumor antigens.
The source describes CAR-T therapy as clinically effective in hematologic malignancies, with approved products targeting CD19 and BCMA.
It provides a targeted cancer immunotherapy approach, with notable success in hematologic malignancies including CD19- and BCMA-directed settings.
It is presented as one of several newer therapeutic directions for NF1-associated tumors.
It addresses the need for effective treatment options in pediatric relapsed or refractory B-ALL. The review highlights durable remissions as a key benefit of the modality.
What it does not solve
The abstract states that CAR-T-related cellular therapies still face tumor microenvironment resistance, antigen escape, manufacturing complexity, cost-effectiveness, and accessibility challenges.
The abstract states that no CAR-T therapy has yet been approved for solid tumors and highlights multiple barriers limiting success there.
The abstract notes persistent barriers including exhaustion, antigen escape, cytokine release syndrome, and neurotoxicity.
The abstract does not provide NF1-specific clinical results or show that the approach is approved.
The abstract states that toxicity, antigen escape, and T-cell exhaustion still limit broader application. It also notes unresolved manufacturing, cost, and long-term outcome issues.
Alternatives
No direct alternative therapy modalities are named in the abstract.
The abstract discusses CAR-T alongside TIL engineering and T-cell receptor innovations as related cellular immunotherapy approaches.
The abstract does not name alternative non-CAR-T treatment modalities.
The abstract does not name non-CAR-T therapeutic alternatives, but it does describe multiple CAR engineering variants and delivery technologies within the CAR-T space.
The abstract contrasts CAR-T therapy with MEK inhibition, AAV-based gene therapy, and oHSV therapy.
The abstract discusses next-generation variants within the CAR-T space, including multi-targeted, armored, universal, and microenvironment-responsive designs, rather than non-CAR-T alternatives.
Evidence Snippets
This review provides a comprehensive analysis of current ACT modalities, including ... chimeric antigen receptor-T cell therapies.
Chimeric antigen receptor (CAR) T cell therapy has emerged as a powerful modality in immuno-oncology, enabling patient-derived T cells to be engineered ex vivo to recognize and eliminate tumor antigens.
The congress discussed cutting-edge developments in chimeric antigen receptor T-cell (CAR-T) therapy.
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies
Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC.
Chimeric antigen receptor T (CAR-T) cell therapy represents a major advance in cancer immunotherapy.
Novel therapeutic strategies, including ... chimeric antigen receptor T cell (CAR-T) therapy targeting NF1-associated tumors, are under active investigation.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL)
ATC therapies characterize various types of immunotherapies but predominantly fall into three established techniques: tumour-infiltrating lymphocyte, chimeric antigen receptor T-cell, and engineered T-cell receptor therapies.
Supporting Sources
Linked Claims
CAR T cell therapy is a powerful immuno-oncology modality that engineers patient-derived T cells ex vivo to recognize and eliminate tumor antigens.
Current ACT modalities discussed for ovarian cancer include tumor-infiltrating lymphocytes, T cell receptor-engineered therapies, and chimeric antigen receptor-T cell therapies.
Quoted textsource-backed
This review provides a comprehensive analysis of current ACT modalities, including tumor-infiltrating lymphocytes, T cell receptor-engineered, and chimeric antigen receptor-T cell therapies.
Targeting FAM168B could expand the therapeutic repertoire of CAR T cell therapy and support more precise and versatile treatment strategies for diverse cancer types.
The unique characteristics of FAM168B suggest that it has potential as a tumor-specific target for CAR T cell development.
No CAR-T therapy has been approved for solid tumors.
The U.S. Food and Drug Administration has approved seven CAR-T therapies targeting CD19 and B-cell maturation antigen for hematologic malignancies.
Key challenges discussed for cellular immunotherapy included tumor microenvironment resistance, antigen escape, manufacturing complexity, cost-effectiveness, and accessibility.
Quoted textsource-backed
Discussions covered key challenges such as tumor microenvironment (TME) resistance, antigen escape, manufacturing complexity, cost-effectiveness, and accessibility.
CAR-T therapy has shown notable clinical success, particularly in CD19- and B-cell maturation antigen-targeted therapies.
Quoted textsource-backed
Despite notable clinical success, particularly in CD19- and B-cell maturation antigen-targeted therapies
Second- to fifth-generation CARs incorporate costimulatory molecules, transcriptional regulation, and logic-gated control to improve efficacy and safety.
Quoted textsource-backed
Over time, the development of second- to fifth-generation CARs has incorporated costimulatory molecules, transcriptional regulation, and logic-gated control to improve efficacy and safety.
CAR-T therapy has revolutionized treatment of hematologic malignancies.
CAR-T therapy targeting NF1-associated tumors is under active investigation.
Quoted textsource-backed
Novel therapeutic strategies, including ... chimeric antigen receptor T cell (CAR-T) therapy targeting NF1-associated tumors, are under active investigation.
CAR-T applications are limited by cell exhaustion, antigen escape, cytokine release syndrome, and neurotoxicity.
Quoted textsource-backed
CAR-T applications face challenges, including cell exhaustion, antigen escape, and therapy-induced toxicities, such as cytokine release syndrome and neurotoxicity.
CRS, ICANS, antigen escape, and T-cell exhaustion hinder broader clinical application of CAR-T therapy in pediatric B-ALL.
Quoted textsource-backed
However, challenges such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), antigen escape, and T-cell exhaustion hinder its broader clinical application.
In colorectal cancer, immunosuppressive microenvironment, tumor heterogeneity, and physical barriers limit CAR-T efficacy.
Major barriers to CAR-T therapy in solid tumors include lack of distinct and accessible target antigens, an immunosuppressive tumor microenvironment, tumor heterogeneity, and off-tumor toxicity risk.
CAR-T therapy engineers autologous T cells with synthetic receptors that enable major histocompatibility complex-independent recognition of tumor-associated antigens.
Quoted textsource-backed
Therapy involves engineering autologous T cells with synthetic receptors that allow major histocompatibility complex-independent recognition of tumor-associated antigens.
CAR-T therapy exerts antitumor effects through granzyme-perforin degranulation, Fas/Fas ligand signaling, and cytokine secretion.
Quoted textsource-backed
CAR-T therapy exerts antitumor effects via granzyme-perforin degranulation, Fas/Fas ligand signaling, and cytokine secretion.
Optimization of antigen recognition, spacer, transmembrane, and intracellular CAR structural components enhances specificity, persistence, and cytotoxicity.
Quoted textsource-backed
Key structural components such as antigen recognition domains, spacers, transmembrane, and intracellular domains are optimized to enhance specificity, persistence, and cytotoxicity.
Viral vectors, transposons, CRISPR/Cas9, and RNA-based electroporation are emerging gene delivery technologies that improve CAR-T production.
Quoted textsource-backed
Emerging gene delivery technologies, including viral vectors, transposons, CRISPR/Cas9, and RNA-based electroporation, are improving CAR-T production.
The congress and review covered adoptive cell transfer, CAR-T therapy, TIL engineering, and TCR innovations as cutting-edge cancer immunotherapy developments.
Quoted textsource-backed
The Second Bone Marrow Transplant and Cellular Therapy Congress ... convened global experts to discuss cutting-edge developments in adoptive cell transfer (ACT); chimeric antigen receptor T-cell (CAR-T) therapy, tumor-infiltrating lymphocyte (TIL) engineering and T-cell receptor (TCR) innovations.
CAR-T cell therapy has emerged as a groundbreaking treatment for pediatric B-cell acute lymphoblastic leukemia, especially in relapsed or refractory disease.
Quoted textsource-backed
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL), especially for patients with relapsed or refractory disease.
CAR-T cell therapy is presented as a promising treatment avenue for solid tumors including colorectal cancer.
Further research is needed to refine manufacturing processes, reduce costs, and improve long-term outcomes for CAR-T therapy in pediatric B-ALL.
Quoted textsource-backed
Despite these innovations, further research is needed to refine manufacturing processes, reduce costs, and improve long-term outcomes.